|
Match
|
Document |
Document Title |
|
|
7605145 |
Micronutrient formulations for treatment of diabetes mellitus
Formulations for minimizing damage to at least one of cells, organs and systems within the body of a subject afflicted with Diabetes Mellitus. The invention additionally encompasses methods for...
|
|
|
7566803 |
Vitamin D receptor modulators
The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These...
|
|
|
7566696 |
Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
Methods for treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally,...
|
|
|
7563783 |
2-methylene-19-nor-(20S-24S)-1α,25-dihydroxyvitamin-D2
Compounds of formula I are provided where X 1 , X 2 , and X 3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions...
|
|
|
7560240 |
Method for monitoring gastrointestinal inflammation in persons with inflammatory bowel disease(IBD)
A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces,...
|
|
|
7541349 |
2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone
Compounds of formula 1A and 1B are provided where X 1 and X 2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions...
|
|
|
7541348 |
2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol
Compounds of formula I are provided where X 1 and X 2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are...
|
|
|
7538098 |
19-nor-vitamin D analogs with 1,2 or 3,2 heterocyclic ring
19-nor-vitamin D analogs having an additional heterocyclic ring connecting the 3β-oxygen and carbon-2 or the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore,...
|
|
|
7534778 |
(20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
This invention discloses (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol
and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of...
|
|
|
7534777 |
Des-C,D analogs of 1α,25-dihydroxy-19-norvitamin D3
Des-C,D 2-methylene-19-norvitamin D 3 analogs are provided including compounds of formula 1, in which R 1 is a straight or branched chain alkyl or alkylene group having from 8 to 27 carbons and...
|
|
|
7531527 |
2-Propylidene-19-nor-vitamin D compounds
2-propylidene-19-nor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by high bone...
|
|
|
7528122 |
Vitamin D analog—NEL, methods and uses thereof
Compounds of formula IA or IB are provided where X 1 , X 2 and X 3 are independently selected from H or hydroxy protecting groups and R 1 is selected from straight or branched chain alkyl groups...
|
|
|
7524980 |
Vitamin D3 lactam derivative
Compounds expressed by the following formula (1) or pharmaceutically permissible solvate thereof which is effective for treating Paget's disease of bone, hypercalcemia or osteoporosis.
In the...
|
|
|
7514469 |
Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent
The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-ring flavonoids and flavans—for use in the prevention and...
|
|
|
7514442 |
Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds,...
|
|
|
7511030 |
2-methylene-19-nor-(20S-24epi)-1α,25-dihydroxyvitamin D2
Compounds of formula I are provided where X 1 , X 2 , and X 3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions...
|
|
|
7511028 |
Use of bisphosphonates for otosclerosis
A method of treating otosclerosis in a human in need thereof by administering a bisphosphonate in a defined dosing schedule. The invention demonstrates an effective response and sustained benefit...
|
|
|
7491712 |
Process for preparation of paricalcitol and intermediates thereof
The invention relates to a novel process for the preparation of Paricalcitol and intermediates thereof.
|
|
|
7491711 |
Methods of treatment using 3-desoxy vitamin D3 analogs
The present invention provides a method for treating osteoporosis, hyperparathyroidism or an autoimmune disease in a patient by administering to the patient a 3-desoxy vitamin D 3 analog of the...
|
|
|
7476404 |
Composition for treatment of bone loss
The composition set forth provides for the treatment of bone loss and osteoporosis. The formulation combines Vitamin D; Calcium Citrate Malate; Potassium Citrate; Magnesium; Boron and Vitamin K....
|
|
|
7470695 |
N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds,...
|
|
|
7468361 |
2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and...
|
|
|
7449451 |
Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
Disclosed herein is a method for protecting humans in need of such protection from physical damage caused by ionizing radiation comprising administering to said humans on a defined basis prior to...
|
|
|
7435725 |
Oral compositions and methods for prevention, reduction and treatment of radiation injury
An oral composition for the prevention, reduction or treatment of radiation injury including one or more compounds that regulates cell differentiation and/or cell proliferation, and one or more...
|
|
|
7402688 |
2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin D derivative
A novel 2,2-di-substituted 19-norvitamin D derivative. It is a compound represented by the general formula (I) wherein R1 and R2 are the same or different and each represents hydroxy and A...
|
|
|
7399755 |
Formulations comprising multiple dietary and endogenously made antioxidants and B-vitamins and use of same
The invention is directed to formulations comprised of multiple dietary and endogenously made antioxidants and B-vitamins and the use of these formulations in preventing and treating coronary...
|
|
|
7390509 |
Compositions and methods for nutrition supplementation
The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, pregnant or...
|
|
|
7332482 |
Method for treating benign prostatic hyperplasia
The use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-
cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the...
|
|
|
7303771 |
Alfalfa sprout powder based supplement
The present disclosure relates to the novel nutritional methods and compositions containing essential alfalfa sprouts powder which reduces certain risk factors of cardiovascular disease...
|
|
|
7279180 |
Stable emulsions and dry powders of mixtures of fat-soluble vitamins, their preparation and use
The present invention relates to stable emulsions and dry powders of mixtures of fat-soluble vitamins, and to processes for their preparation and to their use.
|
|
|
7262224 |
Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof
A cosmetic composition is shown for rejuvenating the appearance of skin with reduced or minimal potential for skin irritation, in the form of a lotion or cream which includes as a major component...
|
|
|
7259143 |
Method of extending the dose range of vitamin D compounds
Inhibitors of bone calcium resorption are administered to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating non-calcium related diseases such as cancer,...
|
|
|
7256184 |
Treatment of aging disorders in humans
A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes....
|
|
|
7244719 |
2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses
This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D 3 and pharmaceutical uses therefor. This...
|
|
|
7241752 |
17,20(E)-dehydro vitamin D analogs and their uses
This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vit
amin D 3 and pharmaceutical uses therefor. This compound...
|
|
|
7241751 |
2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and its uses
This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound...
|
|
|
7241750 |
2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses
This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound...
|
|
|
7241749 |
2α-Methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses
This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D 3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in...
|
|
|
7238681 |
2-Methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol and its uses
This invention discloses 2-methylene-18,19-dinor-vitamin D analogs, and specifically 2-methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol and pharmaceutical uses therefor. This compound...
|
|
|
RE39706 |
Crystalline form of a vitamin D analogue
The present invention relates to calcipotriol hydrate—a new crystalline form of calcipotriol—with superior technical properties and with superior stability.
|
|
|
7232810 |
2-methylene-19-nor-vitamin D2 compounds
2-Methylene-19-nor-24(S) and 24(R) derivatives of 1α,25-dihydroxyvitamin D 2 are disclosed. These compounds are characterized by minimal bone calcium mobilization activity and relatively high...
|
|
|
7220739 |
Therapeutic application of pro-apoptotic benzodiazepines
Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of the...
|
|
|
7214671 |
Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3 . This compound is characterized by high bone calcium mobilization activity demonstrating...
|
|
|
7214670 |
Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3 . Administration of this compound increases the life expectancy of human beings, especially...
|
|
|
7208484 |
Method of synthesizing 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol
A method of making 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol. The method includes the steps of condensing a bicyclic ketone with an allylic phosphine oxide to produce a protected...
|
|
|
7205286 |
(20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
This invention discloses (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D 3 and (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D 3 and pharmaceutical uses therefor. These compounds exhibit pronounced...
|
|
|
7205007 |
Peri-operative and peri-procedure nutritional supplementation
The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury....
|
|
|
7186706 |
Administration of non-oral androgenic steroids to women
The present invention provides compositions, methods, and kits for improving health in a woman having elevated SHBG levels, or who is receiving oral estrogen supplementation, by non-orally...
|
|
|
7179455 |
Pesticide in gel form
The invention relates to a bait matrix which includes a gelling agent and a pesticide. The bait matrix is useful for controlling pests by attracting and poisoning them. The gel matrix is...
|
|
|
7166585 |
24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3
The present invention provides novel C24-sulfone analogs of 1α,25-dihydroxy vitamin D 3 , compositions comprising these compounds and methods of using these compounds as selective inhibitors of...
|